Guardant Health, Inc. (GH)
 NASDAQ: GH · Real-Time Price · USD
 92.41
 +20.14 (27.87%)
  At close: Oct 30, 2025, 4:00 PM EDT
92.00
 -0.41 (-0.44%)
  After-hours: Oct 30, 2025, 7:57 PM EDT
Guardant Health Revenue
Guardant Health had revenue of $265.20M in the quarter ending September 30, 2025, with 38.50% growth. This brings the company's revenue in the last twelve months to $902.57M, up 30.38% year-over-year. In the year 2024, Guardant Health had annual revenue of $739.02M with 31.04% growth.
Revenue (ttm) 
 $902.57M
Revenue Growth 
 +30.38%
P/S Ratio 
 13.79
Revenue / Employee 
 $446,595
Employees 
 2,021
Market Cap 
11.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% | 
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% | 
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% | 
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% | 
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
GH News
- 1 hour ago - Guardant Health: Business Continues To Gather Pace - Seeking Alpha
- 21 hours ago - Guardant Health, Inc. (GH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - Business Wire
- 3 days ago - Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights - Business Wire
- 4 days ago - Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 - Business Wire
- 15 days ago - Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025 - Business Wire
- 21 days ago - Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 - Business Wire
- 4 weeks ago - FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer - Business Wire